

TABLE 6-2. OUTCOMES OF CORTICOSTEROID AND ANTI-VEGF TREATMENT FOR RVO-RELATED MACULAR EDEMA
NONCOMPARATIVE STUDIES

Study (Design)	Therapeutic Combination (Tx Delay)	Patients	F/U	Tx Naïve	Functional Outcomes	Anatomic Outcomes	Injection Number	Adverse Events
Ehrlich 2010 ⁴⁰ (Re)	1.25 mg IVB + 2 mg IVTA (0 d)	BRVO: n = 8 CRVO: n = 8	Min: 6 mo	N	BRVO: ↑ BCVA @ 1 mo (P = .05), 3 mo (P = .03); no change in BCVA @ 6 mo CRVO: no change in BCVA @ 1 mo, 3 mo, 6 mo	BRVO: ↓ CMT @ 6 mo (P = .017) CRVO: ↓ CMT @ 6 mo (P = .005)	2.0 ± 8.1	BRVO: IOP > 21 in 3/8 patients during F/U CRVO: IOP > 21 in 2/8 patients during F/U
Gupta 2011 ⁴¹ (Re) ^a	1.25 mg IVB + 2 mg IVTA (0 d)	CRVO: n = 11	Mean: 14.64 mo	N	No change in final BCVA (P = .69)	No change in final CMT (P = .31)	5.09 ± 5.83	↑ IOP _b = 1/11
Singer 2012 ⁴⁴ (P)	1.25 mg IVB + 0.7 mg Ozurdex (Allergan)	BRVO: n = 22 CRVO: n = 12	6 mo	N	Letters gained @ 1 mo = 12.3; 2 mo = 14.1; 3 mo = 11.0; 6 mo = 16.8 ^c		Time to retreat = 129 d	IOP > 23 in 6/34
Cho 2012 ⁴³ (P, Ra)	Mono: 1.25 mg IVB Combo: 1.25 mg IVB + 40 mg PSTK (0 d)	Mono: n = 30 (all BRVO) Combo: n = 30 (all BRVO)	6 mo	Y	Mono: ↑ BCVA @ 1 mo, 3 mo, 6 mo (all P < .001) Combo: ↑ BCVA @ 1 mo, 3 mo, 6 mo (all P < .001) Intergroup: BCVA combo > mono @ 1 mo (P = .025), 6 mo (P = .002)	Mono: ↓ CMT @ 1 mo, 3 mo, 6 mo (all P < .001) Combo: ↓ CMT @ 1 mo, 3 mo, 6 mo (all P < .001) Intergroup: CMT combo > mono @ 1 mo (P = .026), 3 mo (P = .005), 6 mo (P ≤ .001)	Combo < mono (P = <.001)	(continued)